Alexandra Bray

Alexandra Bray

Associate
Brussels

Email alexandra.bray@​hoganlovells.com

Phone +32 2 505 0975

Fax +32 2 505 0996

LanguagesEnglish, French

Practice groupGlobal Regulatory

Alexandra Bray advises on all aspects of EU competition law, including complex multi-jurisdictional mergers, anticompetitive agreements, cartel and abuse of dominance investigations, compliance training and licensing negotiations.

Prior to joining Hogan Lovells, Alexandra gained experience in various international law firms in Paris. She also worked at the General Court of the European Union where she gained insights into EU trademarks litigation.

Education and admissions

Education

LL.M., HEC Paris, 2017

Master in Comparative European Law, Université Panthéon Assas, 2015

Master in Public Business Law, Université Panthéon Assas, 2014

Bar admissions and qualifications

Paris

Brussels

Related industries

Aerospace and Defense Consumer Energy and Natural Resources Life Sciences and Health Care TMT

Related practices

Antitrust and Competition

Related areas of focus

Abuse of Dominance and Restrictive Practices Antitrust and Competition Litigation Cartel Investigations Competition Compliance Dawn Raids Leniency Applications Merger Control State Aid

Representative experience

Advised Google LLC and Alphabet Inc., before the General Court for the annulment of the EU Commission decision AT.39740 Google Search (Shopping).

Acting for a Japanese electronic component manufacturer challenging an EU cartel fine before the General Court.

Securing global antitrust merger approvals for the acquisition of Primetals Technologies by Mitsubishi Heavy Industries.

Advising a mobile device manufacturer on an arbitration arising from its licensing of standard essential patents (Article 102 TFEU).

Advising Westerkirk in its acquisition of the Q400 program of Bombardier.

Advising a third-party state to the EU in its negotiations to enter into a trade agreement.*

Secured Phase I unconditional clearance before the European Commission of the acquisition of OTC medicines businesses by a global specialty pharmaceutical company.*

*Matter handled prior to joining Hogan Lovells.

Loading data